LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
Podcasts & Webcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
BioCentury-BayHelix China Healthcare Summit
East-West Healthcare Reception
BioCentury-BayHelix East-West Summit
Bio€quity Europe
BioCentury Grand Rounds Inquiry
The BioCentury Show
Webinars - Upcoming & On-Demand
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Beam Therapeutics Inc.
Headquarters:
Cambridge, MA, United States of America
Website:
https://beamtx.com
Year Founded:
2017
Status:
Public
Industry Sector:
HealthTechnology
CEO:
John Evans, MBA
Number Of Employees:
436
Enterprise Value:
$1,083,370,000
PE Ratio:
-15.11
Exchange/Ticker 1:
NASDAQ:BEAM
Exchange/Ticker 2:
N/A
Latest Market Cap:
$2,376,520,704
BioCentury
|
Dec 10, 2024
Product Development
Gene and base editors deliver on fetal hemoglobin expression: ASH24
Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting
Read More
BioCentury
|
Dec 5, 2024
Discovery & Translation
Science Spotlight: Advances in RSV and hMVP vaccines
BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates
Read More
BioCentury
|
Nov 5, 2024
Product Development
Arcus data the latest twist in the TIGIT story
BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
Read More
BioCentury
|
Oct 22, 2024
Finance
Venture funds, a new chapter for MS & Wave’s data: a BioCentury podcast
What Forbion’s $2.2B raise says about the state of venture, NIH’s Daniel Reich on MS and RNA-editing oligo data from Wave
Read More
BioCentury
|
Oct 17, 2024
Product Development
Wave data propel RNA-editing stocks, but are all platforms created equal?
In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
Read More
BioCentury
|
Aug 30, 2024
Emerging Company Profile
Nvelop: Delivering gene editors to specific cells via virus-like particles
Propelled by $100M in seed funding, Cambridge, Mass.-based biotech is developing dual virus-like particle platforms from two gene editing pioneers
Read More
BioCentury
|
Jan 26, 2024
Management Tracks
Karuna vet Paul among new Third Rock venture partners
Plus: three new executives at Soleno and updates from Zentalis, Slingshot, Actio, Kronos, Osivax, Cellular Origins and ConcertAI
Read More
BioCentury
|
Jan 13, 2024
Finance
Jan. 12 Quick Takes: Alto Neuroscience files for IPO
Plus: Company-creating research institute Arena BioWorks launches in Kendall Square, and an update from Ji Xing
Read More
BioCentury
|
Dec 21, 2023
Product Development
Diamonds in a rough 2023, predictions for 2024
BioCentury’s analysts look back at a year when innovation was hot but markets were not, and predict what’ll make news in 2024
Read More
BioCentury
|
Dec 19, 2023
Discovery & Translation
Next-gen gene editing at ASH
Non-Cas9 enzymes and strategies to improve ex vivo and in vivo engineering of hematopoietic cells are among the innovations
Read More
Items per page:
10
1 - 10 of 103